Enlightenment Research’s Biogen BIIB Stock Holding History

Enlightenment Research’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,090	Closed	-$291K	–	8
2022 Q3	$291K	Buy	+1,090	New	+$231K	0.64%	56
2021 Q3	–	Sell	-900	Closed	-$312K	–	145
2021 Q2	$312K	Buy	+900	New	+$273K	0.4%	81

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Enlightenment Research's BIIB Position: Q4 2022 in Review

Enlightenment Research sold out of Biogen (BIIB) in Q4 2022, closing a stake of 1,090 shares — an estimated $291K sold.

Enlightenment Research first reported a position in BIIB in Q2 2021 and held it in 2 quarters. The position peaked at $312K in Q2 2021. 1,032 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Enlightenment Research reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Enlightenment Research sold 1,090 Biogen shares in Q4 2022, an estimated $291K.
Enlightenment Research first reported a position in Biogen in Q2 2021 and held it in 2 quarters.
Enlightenment Research's Biogen position peaked at $312K in Q2 2021.
1,032 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Enlightenment Research's 13F filing for Q4 2022.